First-pass extracted concept

ligand-guided transcytosis and CendR pathway engagement

Candidate: concept label1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This strategy family uses ligand-guided transcytosis, including CendR pathway engagement, to move therapeutics more deeply through tumor tissue.

Source 1DOI PubMed

What problem it solves

It addresses the tendency of tumor-delivered agents to remain near vessels rather than distributing into tumor cores.

Source 1DOI PubMed

What it does not solve

The abstract highlights risks from corona susceptibility and from excessive affinity that can promote perivascular trapping.

Source 1DOI PubMed

Alternatives

The review contrasts this family with switching, microenvironment remodeling, cell-based or biomimetic vectors, and multistage designs.

Source 1DOI PubMed

Evidence Snippets

We organize transformable and bioinspired nanomedicines using a barrier-centric lens and summarize five strategy families to deepen and homogenize intratumoral transport: (iii) ligand-guided transcytosis and CendR pathway engagement

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1design recommendationsupports2026Source 1DOI PubMed

Translational priorities include coupling barrier priming with a single well-characterized switching event, favoring moderated or activatable affinity to avoid perivascular trapping, and validating spatial gains using standardized intratumoral distribution metrics linked to therapeutic endpoints.

Quoted textsource-backed

We conclude with translational priorities: couple barrier priming with a single well-characterized switching event, favor moderated or activatable affinity to avoid perivascular trapping, and validate spatial gains using standardized intratumoral distribution metrics linked to therapeutic endpoints.

Claim 2problem statementsupports2026Source 1DOI PubMed

In solid tumors, therapeutics that reach tumors often remain near vessels and fail to distribute uniformly into tumor cores.

Quoted textsource-backed

therapeutics that reach tumors often remain sequestered near vessels and fail to distribute uniformly into tumor cores

Claim 3strategy summarysupports2026Source 1DOI PubMed

The review summarizes five strategy families for deepening and homogenizing intratumoral transport: stimuli-responsive size/charge switching, microenvironment remodeling, ligand-guided transcytosis and CendR pathway engagement, cell-based and biomimetic vectors, and multistage designs.

Quoted textsource-backed

We organize transformable and bioinspired nanomedicines using a barrier-centric lens and summarize five strategy families to deepen and homogenize intratumoral transport